Karyopharm Therapeutics (KPTI) Non-Current Debt (2024 - 2026)

Karyopharm Therapeutics (KPTI) has reported Non-Current Debt for 3 consecutive years, with $85.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Debt fell 5.05% year-over-year to $85.0 million; the trailing twelve-month figure through Jun 2026 stood at $85.0 million (down 5.05% YoY), and the FY2025 full-year result was $94.8 million, changed 0.2% from the prior year.
• Non-Current Debt slipped to $85.0 million in Q2 2026 per KPTI's latest filing, from $94.8 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $95.2 million in Q1 2025 and bottomed at $83.9 million in Q3 2025.
• Historically, Non-Current Debt has averaged $91.3 million across 3 years, with a median of $93.8 million in 2024.
• The widest YoY moves for Non-Current Debt: up 0.2% in 2025, down 10.85% in 2025.
• Over 3 years, Non-Current Debt stood at $94.6 million in 2024, then grew by 0.2% to $94.8 million in 2025, then fell by 10.28% to $85.0 million in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $85.0 million, $94.8 million, and $83.9 million for Q2 2026, Q4 2025, and Q3 2025 respectively.